Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Campbell P M, LeRoy E C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975; 4: 351-68.

Jayson M I V. Systemic sclerosis: a collagen or microvascular disease? BMJ 1984; 288: 1855-7.

Lee P, Norman C S, Sukenik S, Alderdice C A. The clinical significance of coagulation abnormalities in systemic sclerosis (scleroderma). J Rheumatol 1985; 12: 514-7.

Mannucci P M, Lombardi R, Lattuada A, Perticucci E, Valsecchi R, Remuzzi G. Supranormal von Willebrand factor multimers in scleroderma. Blood 1987; 73: 1586-91.

Belch J J F, Zoma A A, Richards I M, McLaughlin K, Forbes C D, Sturrock R D. Vascular damage and factorVIII-related antigen in the rheumatic diseases. Rheumatol Int 1987; 7: 107-11.

Greaves M, Malia R G, Milford Ward A, et al. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br3J Rheumatol 1988; 27: 281-5.

James J P, Stevens T R J, Hall N D, et al. Factor VIII related antigen in connective tissue disease patients and relatives. BrjRheumatol 1990; 29: 6-9.

Matucci-Cerinic M, Pignone P, Lotti T, et al. Reduced angiotensin converting enzyme plasma activity in scleroderma. A marker of endothelial injury? Jf Rheumatol 1990; 17: 328-30.

Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int JMicrocirc Clin Exp 1992; 11: 375-82.

Blann A D, Illingworth K, Jayson M I V. Mechanisms of endothelial damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993; 20: 1325-30.

Goodfield M J D, Orchard M A, Rowell N R. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. BrJ Haematol 1993; 84: 675-80.

Reilly I A G, Roy L, Fitzgerald G A. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. BMJ 1986; 292: 1037-9.

Kahaleh M B, Osbom R, LeRoy E C. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Int Med 1982; 96: 610-3.

Kallenberg C G M, Vellenga E, Wouda A A, The T H. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. JfRheumatol 1982; 9: 878-84.

Hutton R A, Mikhailidis D P, Bernstein R M, Jeremy J Y, Hughes G R V, Dandona P. Assessment of platelet function in patients with Raynaud's syndrome. _7 Clin Pathol 1984; 37: 182-7.

Siebold J R, Harris J N. Plasma 3-thromboglobulin in the differential diagnosis of Raynaud's phenomenon. JrRheumatol 1985; 12: 99-103.

Lima J, Fonollosa V, Fernandez-Cortijo J, et al. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 1991; 18: 1833-6.

Holland C D, Jayson M I V. Venous blood fibrinolysis and fibrinolytic potential in primary Raynaud's phenomenon and systemic sclerosis associated with Raynaud's phenomenon. In: Black C M, Myers A R, eds. Progressive systemic sclerosis. New York: Gower, 1985; 267-73.

Lau C S, McLaren M, Mackay I, Belch J J F. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon. Ann Rheum Dis 1993; 52: 443-8.

Bachmann F, Kruithof I E K 0. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost 1984; 10: 6-17.

Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthnitis Rheum 1980; 23: 581-90.

Blann A D, Hopkins J, Wmkles J, Wainwright A C. Plasma and serum von Willebrand factor antigen concentrations in connective tissue disorders. Ann Clin Biochem 1992; 29: 67-71.

Gill J C, Endres-Brooks J, Bauer P J, Marks W J, Montgomery R R. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.

Kahaleh M B, Scharstein K K, LeRoy E C. Enhanced platelet adhesion to collagen in scleroderma. Effect of scleroderma plasma and scleroderma platelets. Rheumatol 1985; 12: 468-7 1.

Blann A D. Von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease. J'Rheumatol 1993; 20: 1469-71.

Soma Y, Takehara K, Sato S, Ishibashi Y. Increase in plasma thrombomodulin in patients with systemic sclerosis. Jf Rheumatol 1993; 20: 1444-5.

Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am Jf Clin Pathol 1994; 101: 109-13.

Blann A D, McCollum C N. Adverse influence of cigarette smoking on the endothelium. Thromb Haemost 1993; 70: 707-11.

Dotevall A, Rangemark C, Eriksson E, Kutti J, Wadenvik H, Wennmalm A. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. Thromb Haemost 1992; 68: 583-8.

Belch J J F, McArdle B M, Bums P, Lowe G D 0, Forbes C D. The effects of acute smoking on platelet behaviour, fibrinolysis and haemorheology in habitual smokers. Thromb Haemost 1984; 51: 6-8.

Haire W D, Goldsmith J C, Rasmussen J. Abnormal fibrinolysis in healthy male cigarette smokers: role of plasminogen activator inhibitors. AmJrHematol 1989; 31: 36-40.

Blann A D, Taberner D A. A reliable marker of endothelial cell dysfunction: does it exist? BrJ Haematol. In press.